Last reviewed · How we verify

Achaogen, Inc. — Portfolio Competitive Intelligence Brief

Achaogen, Inc. pipeline: 0 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 0 Phase 2 4 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
antibiotic of Investigator's choice antibiotic of Investigator's choice phase 3 Antibiotic Infectious Disease

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Assistance Publique - Hôpitaux de Paris · 1 shared drug class
  2. Bausch Health Americas, Inc. · 1 shared drug class
  3. BioVersys AG · 1 shared drug class
  4. Bosnalijek D.D · 1 shared drug class
  5. Capital Medical University · 1 shared drug class
  6. Dr. Reddy's Laboratories Limited · 1 shared drug class
  7. Incheon St.Mary's Hospital · 1 shared drug class
  8. Jomaa Pharma GmbH · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Achaogen, Inc.:

Cite this brief

Drug Landscape (2026). Achaogen, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/achaogen-inc. Accessed 2026-05-13.

Related